BioSyent Schedules Q2 and H1 2020 Earnings Release for August 26, 2020
August 17 2020 - 7:30AM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be
reporting its financial results for the three and six months ended
June 30, 2020 on Wednesday, August 26, 2020. A presentation
on the Company’s second quarter and first half 2020 results by René
Goehrum, BioSyent President and CEO, will also be available on the
Company’s website on the date of release.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of
patients. BioSyent supports the healthcare professionals that
treat these patients by marketing its products through its
community, specialty/hospital and international business units.
As of the date of this press release, the
Company has 12,808,170 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024